Healthcare >> Analyst Interviews >> March 28, 2014

Faster FDA Approvals and Paradigm-Shifting Breakthroughs Boost Pharma Stocks

Baum, Andrew
Andrew Baum, M.D., joined Citigroup Investment & Research Analysis in September 2011 as the Global Head of Healthcare Research. Before joining the firm, Dr. Baum was at Morgan Stanley for 14 years where he was the top ranked European Pharmaceutical Analyst in the Extel Poll for six years. Dr. Baum and his team consistently ranked in the top three teams in external EU and global investor polls — Institutional Investor, Greenwich and Reuters. Before this, he was a U.K. Pharmaceutical and Biotechnology Analyst at Salomon Brothers. From 1994 to 1996, he was a practicing Physician at the Royal National Orthopaedic Radcliffe Hospital in Oxford, the medical center of Oxford University, where he completed his residency. Dr. Baum holds an M.A. in physiological sciences and an M.D. from Oxford University. Profile
TWST: It's been a good run for pharma stocks, especially the specialty and generics and those in the biopharma end of the spectrum. What do you see as some of the keys to that outperformance,